Some FXR agonists have applied for the treatment of alcoholic hepatitis, nonalcoholic steatohepatitis, diabetes and primary biliary cirrhosis in clinical trials11, 12, 13, 14. This evidence concerns the gene NR1H4 and diabetes mellitus.